The novel coronavirus infection emerged in Wuhan in the late 2019 which later spread across the globe and was declared as a pandemic in March 2020. The virus was named by World Health Organization as SARS-CoV-2 and the disease caused by it as COVID-19 on 11 February, 2020. The disease leads to respiratory distress syndrome and mortality, especially in elderly and people with comorbidities. The treatment remains supportive, in the absence of specific treatment, prevention is the only answer. Apart from physical distancing, hand washing, and masks, vaccination is a futuristic option. Although work has started in full swing, the vaccine may not be available before 12–18 months. Here, the vaccine scenario changes by the day, but I have tried to evaluate the types of vaccines possible and the ones where trials have started.
World Health Organization. WHO Director-General's remarks at the media briefing on 2019-nCoV on 11 February 2020. 2020.
Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel corona virus-infected pneumonia. N Engl J Med 2020;382(13):1199–1207. DOI: 10.1056/NEJMoa2001316, Accessed on 28 Mar 2020.
Hoffmann M, Kleine-Weber H, Krüger N, et al. The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells. bioRxiv 2020. DOI: 10.1101/2020.01.31.929042.
Zhou P, Yang X-L, Wang X-G, et al. Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin. bioRxiv 2020. DOI: 10.1101/2020.01.22. 914952.
J & J working on coronavirus vaccine. The pharma letter2020. https://www.thepharmaletter.com/article/j-j-working-on-coronavirusvaccine.
Cheung E. China coronavirus: Hong Kong researchers have already developed vaccine but need time to test it, expert reveals. South China Morning Post. https://www.scmp.com/news/hong-kong/health-environment/article/3047956/china-coronavirus-hongkong-researchers-have.
Shieber J. Codagenix raises $20 million for a new flu vaccine and other therapies. Tech Crunch. https://techcrunch.com/2020/01/13/codagenix-raises-20-million-for-a-new-flu-vaccine-and-othertherapies/.
Jiang S, Bottazzi ME, Du L, et al. Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome. Expert Rev Vaccines 2012;11(12):1405–1413. DOI: 10.1586/erv.12.126.
Coleman CM, Liu YV, Mu H, et al. Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mICE. Vaccine 2014;32(26):3169–3174. DOI: 10.1016/j.vaccine.2014. 04.016.
Clover Biopharmaceuticals. Clover initiates development of recombinant subunit-trimer vaccine for Wuhan coronavirus (2019nCoV). 2020.
Chen WH, Chag SM, Poongavanam MV, et al. Optimization of the production process and characterization of the yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1), a SARS vaccine candidate. J Pharm Sci 2017;106(8):1961–1970. DOI: 10.1016/j.xphs.2017.04.037.
RNA vaccines an introduction. https://www.phgfoundation.org/briefing/rna-vaccines.
NIH clinical trial of Investigational vaccine for Covid. https://www.nih.gov/news-events/news-releases/nih-clinical-trial-investigational-vaccine-covid-19-begins.
The Covid vaccine development landscape. https://www.nature.com/articles/d41573-020-00073-5.
University of Oxford commences clinical trial for vaccine. https://www.trialsitenews.com/university-of-oxford-commences-clinical-trial-for-vaccine-candidate-chadox1-ncov-19-targeting-covid-19-2/.